Back to Search
Start Over
A factor IX variant that functions independently of factor VIII mitigates the hemophilia A phenotype in patient plasma
- Source :
- Journal of Thrombosis and Haemostasis, 21(6), 1466-1477. Wiley-Blackwell Publishing Ltd
- Publication Year :
- 2023
-
Abstract
- Background: Recombinant factor (F)IX-FIAV has previously been shown to function independently of activated FVIII (FVIIIa) and ameliorate the hemophilia A (HA) phenotype in vitro and in vivo. Objectives: The aim of this study was to assess the efficacy of FIX-FIAV in plasma from HA patients using thrombin generation (TG) and intrinsic clotting activity (activated partial thromboplastin time [APTT]) analyses. Methods: Plasma obtained from 21 patients with HA (>18 years; 7 mild, 7 moderate, and 7 severe patients) was spiked with FIX-FIAV. The FXIa-triggered TG lag time and APTT were quantified in terms of FVIII-equivalent activity using FVIII calibration for each patient plasma. Results: The linear, dose-dependent improvement in the TG lag time and APTT reached its maximum with approximately 400% to 600% FIX-FIAV in severe HA plasma and with approximately 200% to 250% FIX-FIAV in nonsevere HA plasma. The cofactor-independent contribution of FIX-FIAV was therefore suggested and confirmed by the addition of inhibitory anti-FVIII antibodies to nonsevere HA plasma, resulting in a FIX-FIAV response similar to severe HA plasma. Addition of 100% (5 μg/mL) FIX-FIAV mitigated the HA phenotype from severe to moderate (from
- Subjects :
- Hematology
Subjects
Details
- Language :
- English
- ISSN :
- 15387933
- Database :
- OpenAIRE
- Journal :
- Journal of Thrombosis and Haemostasis, 21(6), 1466-1477. Wiley-Blackwell Publishing Ltd
- Accession number :
- edsair.doi.dedup.....56ac9a31f2bdace52bcd89caa7361f17